Peptides/Tesamorelin

Tesamorelin

approved

GHRH analog for visceral fat reduction and growth hormone stimulation

GHRH analog
Type
SC injection
Route
Yes — vendors
Available in Thailand
Limited
Clinic therapy

Availability in Thailand

Tesamorelin is available from Thai peptide vendors and select anti-aging clinics in Bangkok. It is one of the few GH-related peptides with formal regulatory approval (for HIV-associated lipodystrophy), though it is typically used off-label for visceral fat reduction and anti-aging.

Prescription: Not required from peptide vendors in Thailand.

Legal status: Has regulatory approval in some countries for HIV lipodystrophy. Available as a research peptide in Thailand.

Where to Buy in Thailand

Tesamorelin pricing varies by vendor. Often more expensive than CJC-1295 due to higher daily dosing requirements. Check vendor websites for current rates.

Vendors

Synergy Peptides

Bangkok

Premium GMP-certified peptides with verified COAs

View vendor →

Clinics

FRESH GENETIQ

Bangkok

Anti-aging and body composition programs

View clinic →

Overview

Tesamorelin is a synthetic 44-amino acid analog of growth hormone-releasing hormone (GHRH) that stimulates the pituitary gland to produce and release natural growth hormone. It is one of the few GH-related peptides with formal regulatory approval — approved for reducing visceral abdominal fat in HIV-associated lipodystrophy. Its ability to specifically target visceral fat while stimulating natural GH production has made it popular beyond its approved indication.

How It Works

GHRH receptor stimulation

Tesamorelin binds to GHRH receptors on pituitary somatotroph cells, stimulating the synthesis and pulsatile release of endogenous growth hormone. The trans-3-hexenoic acid modification improves stability over native GHRH.

Visceral fat targeting

Clinical trials demonstrated specific reduction in visceral adipose tissue (the dangerous fat surrounding organs) with tesamorelin. This effect appears driven by GH-mediated lipolysis concentrated in visceral fat stores, which are more responsive to GH than subcutaneous fat.

IGF-1 elevation

By stimulating natural GH production, tesamorelin downstream increases IGF-1 levels. This supports muscle maintenance, cellular repair, and metabolic health — without the risks of exogenous GH injection.

Protocol Quick Reference

starting Dose
2 mg/day
maintenance Dose
2 mg/day
escalation
Not typically escalated — 2 mg is the standard therapeutic dose
injection Sites
Subcutaneous — abdomen
full Titration
Not applicable — consistent dose from start
cycle Length
12-26 weeks. Clinical trials ran 26 weeks. Some protocols cycle 12 weeks on / 4 weeks off
storage
Refrigerated 2-8°C
reconstitution
Reconstitute lyophilised powder with sterile or bacteriostatic water
timing
Morning, on an empty stomach
special Notes
Unlike CJC-1295 which can be dosed less frequently, tesamorelin requires daily injection due to its shorter half-life. Results for visceral fat reduction typically become measurable after 8-12 weeks.

Benefits & Uses

  • Visceral fat reduction: Clinical trials showed significant reduction in visceral abdominal fat, the metabolically dangerous fat surrounding organs
  • Liver fat reduction: Research demonstrated reduced hepatic steatosis (liver fat) — relevant for metabolic health
  • Natural GH stimulation: Raises GH and IGF-1 through the body's own production pathways, not exogenous injection
  • Body composition improvement: Supports lean mass preservation while reducing fat, particularly in the abdominal area
  • Regulatory approval history: One of the few GH-related peptides with formal approval — stronger safety evidence than most research peptides
  • Anti-aging effects: GH and IGF-1 elevation supports skin quality, recovery, and cellular repair

Side Effects

Common

  • Injection site reactions (redness, swelling, pain)
  • Mild joint stiffness or pain
  • Peripheral oedema (swelling in hands/feet)
  • Mild nausea

Less Common

  • Headache
  • Muscle pain
  • Tingling or numbness in extremities
  • Mild flu-like symptoms during initial use

Serious

  • Elevated IGF-1 carries theoretical cancer risk — avoid with active or recent cancer
  • May affect blood sugar — monitor in diabetic patients
  • Not recommended during pregnancy
  • Can cause fluid retention — caution with heart failure or kidney disease

Related Peptides

FAQ

How does tesamorelin compare to CJC-1295?

Both are GHRH analogs that stimulate natural GH production. Tesamorelin has the advantage of formal regulatory approval and strong clinical data specifically for visceral fat reduction. CJC-1295 is dosed less frequently (daily vs weekly for the DAC version) and is typically combined with ipamorelin. Tesamorelin requires daily injection and is generally more expensive.

How long before I see fat loss results?

Visceral fat reduction typically becomes measurable after 8-12 weeks of consistent daily use. Clinical trials ran for 26 weeks to demonstrate full effects. Surface-level body composition changes take longer to become visually apparent.

Is tesamorelin only for HIV patients?

Its regulatory approval is specifically for HIV-associated lipodystrophy, but it is widely used off-label for visceral fat reduction and anti-aging by people without HIV. The mechanism of action — stimulating natural GH to target visceral fat — works regardless of HIV status.

Disclaimer

This information is for educational purposes only and does not constitute medical advice. Peptides should be used under the guidance of a qualified healthcare professional. Individual results vary. Always consult your doctor before starting any peptide therapy.